Andrew Rettew, DO
Hematology & Oncology · West Reading, PANPI 1215370689
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,775 of the $163,554 with a category attached, or 67.7%. 22 manufacturers reported payments, led by Rigel Pharmaceuticals, Inc. at 41.9% of the total. Reporting peaked in 2023 at $71,637 and has fallen 57.8% since, to $30,202 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $1003.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$69K
- AstraZeneca$57K
- Sobi, Inc$28K
- E.r. Squibb & Sons, L.L.C.$8K
- Incyte Corporation$241
- Bristol Myers Squibb$209
- plus $1K from 16 others
Across 14 payments — averaging $6570.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$34K
- Beone Medicines USA, Inc.$31K
- AbbVie$26K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$32,72520%
- Speaking & faculty fees$110,77568%
- Travel & lodging$14,6759%
- Food & beverage$4,6453%
- Education$7340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 44 | $68,591 |
| AstraZeneca(2 entities) | 43 | $56,621 |
| Sobi, Inc | 15 | $28,314 |
| E.r. Squibb & Sons, L.L.C. | 9 | $8,471 |
| Incyte Corporation | 4 | $241 |
| Bristol Myers Squibb | 12 | $209 |
| Servier Pharmaceuticals LLC | 4 | $159 |
| BTG International Inc. | 7 | $148 |
| Astellas Pharma US Inc | 5 | $136 |
| Amgen | 5 | $100 |
| Gilead | 1 | $95 |
| ADC Therapeutics America, Inc. | 1 | $95 |
| Seagen Inc. | 1 | $86 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $80 |
| Johnson & Johnson | 2 | $37 |
| Merck | 2 | $35 |
| AbbVie | 1 | $34 |
| Pfizer | 2 | $27 |
| Verastem, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Spectrum Pharmaceuticals Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$163,554 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 86 | $1,248,615 |
| VenclextaVenetoclax | 74 | $739,625 |
| VonjoPacritinib Citrate | 27 | $683,182 |
| SprycelDasatinib | 31 | $403,567 |
| PomalystPomalidomide | 11 | $255,239 |
| RevlimidLenalidomide | 14 | $250,491 |
| ImbruvicaIbrutinib | 14 | $205,172 |
| Lenalidomide | 16 | $190,326 |
| CalquenceAcalabrutinib Maleate | 12 | $171,496 |
| Imatinib Mesylate | 41 | $71,997 |
| Acyclovir | 91 | $2,570 |
| ValacyclovirValacyclovir Hcl | 34 | $2,126 |
| Cefpodoxime Proxetil | 11 | $1,942 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $1,547 |
| Hydroxyurea | 55 | $846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $34 | $739,62574 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $8,471 | $658,80642 claims |
| Bristol Myers SquibbRevlimid | $209 | $250,49114 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $80 | $205,17214 claims |
| AstraZenecaCalquence | $56,621 | $171,49612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in West Reading
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.